{"ok":true,"entity":{"id":"merck-co","name":"Merck & Co.","entityType":"company","officialName":"Merck & Co., Inc.","canonicalName":"Merck & Co.","displayName":"Merck & Co.","category":"大手製薬企業","shortDescription":"米国ニュージャージー州ラーウェイに本社を置く研究開発型のバイオ医薬品企業で、米国・カナダ以外では「MSD」の社名で事業を展開する（ドイツのMerck KGaAとは別法人）。抗PD-1抗体Keytruda（pembrolizumab）を中心とする腫瘍領域を最大の柱とし、GardasilなどのワクチンとMerck Animal Healthによるアニマルヘルス事業を併せ持つ。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.merck.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":["MSD"],"searchKeywords":["腫瘍","ワクチン","Keytruda","Gardasil"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-04-002"]}